Last reviewed · How we verify
A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease
This project is the stage of dose escalation, is was divided into single and multiple dose clinical study, This is a multi-center, randomized, double-blind, placebo-controlled , study to the safety, tolerability and pharmacokinetic characteristics of TQC3927 powder for inhalation in Chronic Obstructive Pulmonary Disease
Details
| Lead sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 48 |
| Start date | Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Aug 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
- TQC3927 powder for inhalation
- TQC3927 powder for inhalation placebo
Countries
China